Inovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Maxim Affirms Inovio Pharma (INO) at 'Buy' Following Q4 Results, Asset Acquisition
March 14, 2016 2:45 PM EDTMaxim affirmed Inovio Pharma (Nasdaq: INO) with a Buy rating and $14 price target following Q4 results and acquisition of Bioject Medical Technologies' Needle-Free Injection Technology earlier Monday.
Analyst Jason Kolbert noted the following
Immune oncology: A phase III study for VGX-3100 is expected... More